Functional outcomes with esketamine in treatment-resistant depression: A 6-month multicenter real-world study.
European Psychiatry June 10, 2026 Riccardo Guglielmo, Miriam Olivola, Alberto Inuggi et al.
Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...
DOI: 10.1192/j.eurpsy.2026.12233 (opens in new tab)
Full text (opens in new tab)
Esketamine
Treatment-resistant depression
Functional remission
Long-term outcomes
+1